Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 321-327

  Gardin, Claude ^a   Chevret, Sylvie ^b   Pautas, Cécile ^c   Turlure, Pascal ^d   Raffoux, Emmanuel ^b   Thomas, Xavier ^e   Quesnel, Bruno ^f   De Revel, Thierry ^g   De Botton, Stéphane ^h   Gachard, Nathalie ^d   Renneville, Aline ^f   Boissel, Nicolas ^b   Preudhomme, Claude ^f   Terré, Christine ⁱ   Fenaux, Pierre ^a   Bordessoule, Dominique ^d   Celli Lebras, Karine ^b   Castaigne, Sylvie ⁱ   Dombret, Hervé ^b  

^a UNIVERSITÉ PARIS 13   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITY OF LIMOGES   (France)

^e UNIVERSITÉ LUMIÈRE LYON 2   (France)

^f UNIV LILLE   (France)

^g Hôpital des Armées   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CORE BINDING FACTOR; DAUNORUBICIN; IDARUBICIN; NUCLEOPLASMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CONVALESCENCE; DRUG MEGADOSE; FEMALE; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; LONG TERM CARE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IDARUBICIN; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TIME; TREATMENT OUTCOME;

EID: 84873335475     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.3642     Document Type: Article

References (39)

1. Löwenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 341:1051-1062, 1999 (Pubitemid 29451802)
2. Rowe JM: Treatment of acute myelogenous leukemia in older adults. Leukemia 14:480-487, 2000 (Pubitemid 30142876)
3. Estey EH: How I treat older patients with AML. Blood 96:1670-1673, 2004
4. Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood 107:3481-3485, 2006
5. Bacher U, Kern W, Schnittger S, et al: Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 90:1502-1510, 2005 (Pubitemid 41658763)
6. Frö hling S, Schlenk RF, Kayser S, et al: Cytogenetics and age are the major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from the AMLSG trial AML HD98-B. Blood 108:3280-3288, 2006
7. Farag SS, Archer KJ, Mrózek K, et al: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 108:63-73, 2006 (Pubitemid 43996625)
8. Kantarjian H, O'Brien S, Cortes J, et al: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 106:1090-1098, 2006
9. Malfuson JV, Etienne A, Turlure P, et al: Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 93:1806-1813, 2008
10. Wheatley K, Brookes CL, Howman AJ, et al: Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 145:598-605, 2009
11. Röllig C, Thiede C, Gramatzki M, et al: A novel prognostic model in elderly patients with acute myeloid leukemia: Results of 909 patients entered into the prospective AML96 trial. Blood 116:971-978, 2010
12. Krug U, Röllig C, Koschmieder A, et al: Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet 376:2000-2008, 2010
13. Kantarjian H, Ravandi F, O'Brien S, et al: Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116:4422-4429, 2010
14. Schlenk RF, Dö hner K, Kneba M, et al: Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia: Results from the AMLSG Trial AML HD98B. Haematologica 94:54-60, 2009
15. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 28:596-604, 2010
16. Rao AV, Valk PJ, Metzeler KH, et al: Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 27:5580-5586, 2009
17. Schneider F, Hoster E, Unterhalt M, et al: NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 113:5250-5253, 2009
18. Pautas C, Merabet F, Thomas X, et al: Randomized study of intensified anthracycline doses for nduction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. J Clin Oncol 28:808-814, 2010
19. Gardin C, Turlure P, Fagot T, et al: Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial Blood 109:5129-5135, 2007
20. Itzykson R, Gardin C, Pautas C, et al: Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: A comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica 96:837-844, 2011
21. Fernandez HF, Sun Z, Yao X, et al: Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361:1249-1259, 2009
22. Lowenberg B, Ossenkoppele GJ, van Putten W, et al: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361 1235-1248, 2009
23. Mittelman F (ed): International System for Human Cytogenetic Nomenclature: Guidelines for cancer cytogenetics, in Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1991, pp 1-53
24. Dohner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia n adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
25. 24a. French National Institute for Statistics and Economical Studies: Tables de mortalité, 2002-2004, France entière. http://www.insee.fr/fr/themes/detail.asp?ref-id=ir-sd2004&page=irweb/sd2004/ dd/sd2004-deces.htm
26. Cox DR: Regression models and life tables J R Stat Soc B 34:187-220, 1972
27. Lambert PC: Modeling of the cure fraction in survival studies. Stata J 7:351-375, 2007
28. Tai P, Yu E, Cserni G, et al: Minimum follow-up time required for the estimation of statistical cure of cancer patients: Verification using data from 42 cancer sites in the SEER database. BMC Cancer 5:48-56, 2005
29. Yanada M, Garcia-Manero G, Borthakur G, et al: Potential cure of acute myeloid leukemia: Analysis of 1069 consecutive patients in first complete remission. Cancer 110:2756-2760, 2007 (Pubitemid 350250346)
30. Derolf AR, Kristinsson SY, Andersson TM, et al: Improved patient survival for acute myeloid leukemia: A population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 113:3666-3672, 2009
31. Andersson TM, Lambert PC, Derolf AR, et al Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study. Br J Haematol 148:918-924, 2009
32. Ohtake S, Miyawaki S, Fujita H, et al: Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSG AML201 study. Blood 117:2358-2365, 2011
33. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, et al: CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 86:329-337, 2007 (Pubitemid 46477296)
34. Raaijmakers MH, de Grouw EP, Heuver LH, et al: Breast cancer resistance protein in drug resistance of primitive CD34+38-cells in acute myeloid leukemia. Clin Cancer Res 11:2436-2444, 2005 (Pubitemid 40490205)
35. Berman E, McBride M: Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267-3273, 1992
36. Cashen AF, Schiller GJ, O'Donnell MR, et al Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 28:556-561, 2010
37. Burnett AK, Russell NH, Kell J, et al: European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 28:2389-2395, 2010
38. Kantarjian HM, Erba HP, Claxton D, et al Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28:549-555, 2010
39. Ravandi F, Issa JP, Garcia-Manero G, et al Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 115:5746-5751, 2009